Small cap round-up: Angel Biotechnology, Glanbia, MBL Group

Angel Biotechnology has signed an agreement with arGentis Pharmaceuticals that could see it manufacture the firm's ARG201 drug, a treatment for the life-threatening autoimmune disease, systemic sclerosis. Angel's stock rose 6.6% in morning trading.

Angel Biotechnology has signed an agreement with arGentis Pharmaceuticals that could see it manufacture the firm's ARG201 drug, a treatment for the life-threatening autoimmune disease, systemic sclerosis. Angel's stock rose 6.6% in morning trading.

Glanbia, a nutritional solutions and cheese maker, has announced plans to enter a joint venture to incorporate the business and assets of Dairy Ingredients Ireland. The business is the largest dairy ingredients processor in Ireland, assembling a milk pool of 1.6bn litres and processing it into around 180,000 tonnes of ingredients, largely for export. The group also reported first half results on Wednesday showing pre-tax profits up 24% on the prior year. Glanbia's shares were up 4% at 11:28.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.